FEMYHealthcare · Medical Instruments & SuppliesThe 3 Wall Street analysts covering Femasys, Inc. hold a median 12-month price target of $10 — +235.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Femasys, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Value (12): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on FEMY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +235.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | Lake Street | Maintains | Buy | $30 → $10 |
| 14 Aug 2026 | Maxim Group | Maintains | Buy | $30 → $10 |
| 3 Mar 2026 | Lake Street | Initiates | Buy | $1.50 |
| 3 Mar 2026 | Lake Street | Initiates | Buy | — |
| 20 Nov 2025 | Laidlaw & Co. | Initiates | Buy | — |
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2025 | Jones Trading | Maintains | Buy | — |
| 9 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FEMY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Femasys, Inc. returned −73.9% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 14% of US stocks
Cheaper than 67% of US stocks
Cheaper than 69% of US stocks
Higher than 12% of US stocks
Higher than 63% of US stocks
Higher than 76% of US stocks
Higher than 5% of US stocks
Higher than 97% of US stocks
Higher than 4% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Femasys, Inc. has a market value of $24.8M and an enterprise value of $28.1M.
Revenue in the twelve months to 31 Mar 2026: $2.4M. The latest quarter shrank 18.9% year on year.
Net income over the same four quarters: −$11.9M, a −500.0% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$18.7M, after $508K of capital spending.
Trailing P/E: −0.3×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Femasys, Inc. employs 51 people — $47K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Femasys, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The U.S. Food and Drug Administration authorized the modular premarket approval application pathway for FemBloc, Femasys' non-surgical permanent birth control technology. This represents a regulatory milestone for the device.
Why it matters — For FEMY watchers, this establishes a clearer regulatory route for FemBloc, potentially advancing its path toward FDA approval.
Femasys reported financial results for the second quarter ended June 30, 2026 and provided a corporate update, highlighting that $30 million in financing will support the U.S. commercial strategy for its FemaSeed fertility portfolio and advancement of its FemBloc clinical and regulatory program toward U.S. approval.
Why it matters — FEMY watchers would care because the financing and stated progress on both the FemaSeed commercial strategy and FemBloc regulatory pathway signal continued execution toward key U.S. milestones for the company's core product portfolio.
Femasys announced that it has received new patents in the U.S. and key international markets for the blended polymer component of its non-surgical permanent birth control technology, FemBloc. These patents complement existing delivery system patents and extend the company's global intellectual property protection for the FemBloc solution.
Why it matters — The issuance of these patents strengthens and extends Femasys' intellectual property protection for FemBloc, which may enhance its competitive position in a regulated market.
Femasys announced a $30 million private placement with accredited investors, led by Nantahala Capital and joined by other healthcare-focused funds and company management, with potential additional proceeds from warrant exercises.
Why it matters — A FEMY watcher would care because the financing brings new institutional investors and provides capital that could support the company's operations and development of its fertility and birth control solutions.
The 3 Wall Street analysts covering Femasys, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Femasys, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Femasys, Inc. 50 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Femasys, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +235.6% from the last close, and Ticker Nerd's factor model ranks Femasys, Inc. 50 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Femasys, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FEMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $23 over the next 12 months.
Femasys, Inc. returned -73.9% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Femasys Inc. is a biomedical company specializing in innovative solutions for women’s reproductive health.
The most recent item we track (Benzinga, 19 Aug 2026): "Femasys Secures FDA Pathway for Non-Surgical Contraceptive". The U.S. Food and Drug Administration authorized the modular premarket approval application pathway for FemBloc, Femasys' non-surgical permanent birth control technology. This represents a regulatory milestone for the device.
Femasys Inc. is a biomedical company specializing in innovative solutions for women’s reproductive health. The company focuses on minimally invasive, non-surgical technologies designed to be administered in the physician’s office, aiming to improve patient experience and streamline care pathways. Its current portfolio centers on infertility treatment, diagnostic imaging, and gynecologic interventions. Key products include FemaSeed Intratubal Insemination, an infertility treatment intended to deliver sperm directly into the fallopian tube, and FemVue, a companion diagnostic that enables ultrasound-based assessment of the fallopian tubes. Femasys Inc. also offers FemCerv, a device for cervical tissue sampling to support cervical cancer diagnosis, along with FemCath and FemChec for fallopian tube evaluation. In addition, the company is developing FemBloc as a non-surgical option for permanent birth control. Headquartered in the United States, Femasys Inc. serves healthcare providers in domestic and international markets, addressing significantly underserved areas within women’s healthcare.
CEO Ms. Kathy Lee-Sepsick M.B.A. · 51 employees · United States · https://femasys.com
